Cathy Sila, MD
Neurology · Cleveland, OHNPI 1821034190
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,375 of the $16,705 with a category attached, or 98.0%. 10 manufacturers reported payments, led by AstraZeneca at 51.8% of the total. Reporting peaked in 2022 at $8,625 and has fallen 92.5% since, to $650 in 2024.
Across 31 payments — averaging $538.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Genentech, Inc.$8K
- Portola Pharmaceuticals, LLC$83
- Genentech USA, Inc.$61
- Novartis$48
- Jazz Pharmaceuticals Inc.$25
- plus $90 from 4 others
Across 7 payments — averaging $11,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$80K
- Medtronic$1K
What the payments were for
- Consulting fees$16,37598%
- Food & beverage$3302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $8,647 |
| Genentech, Inc. | 6 | $7,750 |
| Portola Pharmaceuticals, LLC | 6 | $83 |
| Genentech USA, Inc. | 5 | $61 |
| Novartis | 4 | $48 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| UCB, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Sanofi | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Activase$7,125
- Cathflo Activase$7,125
- TNKase$7,125
How this compares
$16,705 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $24,160 |
| Levetiracetam | 120 | $5,009 |
| Memantine Hcl | 17 | $1,297 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,235 |
| Oxcarbazepine | 22 | $1,063 |
| ClopidogrelClopidogrel Bisulfate | 39 | $575 |
| Mirtazapine | 11 | $357 |
| Atorvastatin Calcium | 27 | $286 |
| Donepezil Hcl | 18 | $205 |
| Baclofen | 12 | $199 |
| Rosuvastatin Calcium | 16 | $171 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.